The HIV+Hepatitis Policy Institute is a leading HIV and hepatitis policy organization promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. We strongly support House File 3611 which would require health insurers to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums.
CMS responds to request for information regarding reporting on pharmacy benefits and prescription drug costs
On behalf of the Centers for Medicare & Medicaid Services (CMS), thank you for the letter regarding the Request for Information (RFI) Regarding Reporting on Pharmacy Benefits and Prescription Drug Costs1. The 58 organizations that signed this correspondence are the voice for many individuals who rely on affordable prescription drugs to treat their health conditions and prevent others, and we appreciate hearing from you on this important issue.
111 HIV & LGBT organizations request funding for national PrEP grant program
The undersigned 111 public health, HIV, hepatitis, and STD community-based organizations, along with providers, community health centers, and advocacy organizations are writing to urge you to support the creation of a national PrEP grant program to prevent HIV in the United States.
Letter in support for MS SB 2470 so that patients can afford their prescription medications
[HIV+Hepatitis Policy Institute] strongly supports [MS] Senate Bill 2470, which would require health insurers to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums and ask that you conduct a hearing on the bill as soon as possible.
Comments on the USPSTF draft research plan “Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis”
We urge the USPSTF to consider the following two recommendations as it finalizes its plan “Prevention of Human Immunodeficiency Virus (HIV) Infection: Preexposure Prophylaxis”: research should explicitly evaluate and describe the ancillary services that are integral to the PrEP intervention and the USPSTF should adopt a more nimble and timely review of the PrEP recommendation as new products see clinical trial success.